Bedrijfsoverzicht
CalciMedica, Inc. is a clinical-stage biopharmaceutical entity dedicated to developing therapeutics designed to address illnesses stemming from inflammatory and immunologic processes as well as direct cellular damage. The company operates within the healthcare sector, specifically in the biotechnology industry, a classification that defines its reliance on research and development to advance novel treatments for medical conditions. Its current scale is characterized by a market capitalization of $9.73 million and an operational workforce comprising 16 employees. The combination of a sub-$10 million market cap and N/A annual revenue figures indicates that the company is a micro-cap entity in a pre-revenue or early-stage development phase, where valuation is driven primarily by pipeline potential rather than established sales performance.
Financiële gezondheid
The company reported N/A for revenue over the trailing twelve months, while the net income for the same period stands at a loss of $-29,562,000 and EBITDA is recorded at $-23,075,000. The significant disparity between the reported revenue of N/A and the substantial net income loss of $-29,562,000 reveals a cost structure dominated by high fixed costs associated with clinical-stage research, development, and operational overhead, as there are no revenue streams to offset these expenses. Free cash flow stands at $-13,020,375, which indicates a continuous outflow of capital required to sustain operations and fund the clinical trials necessary for product advancement. All three margin metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, reflecting the absence of realized sales and the accrual of expenses before any revenue can be recognized to calculate profitability. The balance sheet shows cash holdings of $13.02M against total debt of $9.70M, with a debt-to-equity ratio listed as N/A due to the equity dynamics in a loss-making entity. Despite the presence of debt, the cash position exceeds obligations, suggesting a liquidity buffer, though the negative earnings pressure remains a critical factor. The current ratio is 3.58, which indicates a strong ability to meet short-term liabilities with its current assets, providing a layer of financial stability despite operational losses. Return on Equity is -761.0% and Return on Assets is -86.6%, metrics that reveal management's current inability to generate positive returns on the capital base, a common characteristic for biotechnology firms in the clinical development stage where capital deployment precedes commercial success.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is N/A, while the forward P/E is -0.38, a difference that implies the market is pricing in expected future earnings that are currently negative but potentially improving as the company transitions from clinical to commercial phases. The price-to-book ratio is -1.44, a figure that indicates the market is valuing the company at a significant discount relative to its book value, often reflecting the high risk associated with its unproven product candidates and the likelihood of future impairment charges. Alternative valuation metrics such as the price-to-sales ratio, which is N/A, and the EV/EBITDA of -0.28, suggest that traditional valuation multiples are not applicable due to the lack of positive earnings and sales, forcing investors to rely on qualitative assessments of the pipeline. The 52-week high is $7.20 and the 52-week low is $0.46, placing the current trading environment within a wide historical range that highlights significant price volatility over the last year. The beta value of 1.09 indicates that the stock's price volatility is slightly higher than the broader market, suggesting that price movements will likely exceed market averages during periods of heightened uncertainty or interest rate changes.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, reflecting the company's status as a pre-revenue entity where historical growth rates cannot be calculated due to the absence of a consistent sales base. Since the company is not a dividend payer, there is no dividend yield or payout ratio to report, meaning the entity does not distribute cash to shareholders and instead retains all available resources, including the $13.02M cash balance, to fund ongoing research and development activities. The absence of a dividend yield and the N/A growth rates summarize an overall profile focused exclusively on capital appreciation potential through future product approvals rather than current income generation or historical earnings expansion. This growth and income profile is typical for early-stage biotechnology companies that prioritize reinvestment in clinical trials over shareholder distributions.